Drug Recalls



EpiPen and EpiPen Jr. Auto Injectors - Meridian Medical Technologies

On March 31, 2017 the U.S. Food and Drug Administration (FDA) announced that Meridian Medical Technologies, a Pfizer and Mylan manufacturing partner, initiated a voluntary recall of select lots of EpiPen and EpiPen Jr Auto-Injectors. This recall includes the following lot numbers:

Product/Dosage NDC Number Lot Number Expiration Date
EpiPen Jr Auto-Injector, 0.15 mg 49502-501-02 5GN767 April 2017
EpiPen Jr Auto-Injector, 0.15 mg 49502-501-02 5GN773 April 2017
EpiPen Auto-Injector, 0.3 mg 49502-500-02 5GM631 April 2017
EpiPen Auto-Injector, 0.3 mg 49502-500-02 5GM640 May 2017
EpiPen Jr Auto-Injector, 0.15 mg 49502-501-02 6GN215 September 2017
EpiPen Auto-Injector, 0.3 mg 49502-500-02 6GM082 September 2017
EpiPen Auto-Injector, 0.3 mg 49502-500-02 6GM072 September 2017
EpiPen Auto-Injector, 0.3 mg 49502-500-02 6GM081 September 2017
EpiPen Auto-Injector, 0.3 mg 49502-500-02 6GM088 October 2017
EpiPen Auto-Injector, 0.3 mg 49502-500-02 6GM199 October 2017
EpiPen Auto-Injector, 0.3 mg 49502-500-02 6GM091 October 2017
EpiPen Auto-Injector, 0.3 mg 49502-500-02 6GM198 October 2017
EpiPen Auto-Injector, 0.3 mg 49502-500-02 6GM087 October 2017

This recall has been initiated due to the potential that these devices may contain a defective part that may result in the devices’ failure to activate. While the number of reported failures is small, EpiPen products that potentially contain a defective part are being recalled because of the potential for life-threatening risk if a severe allergic reaction goes untreated. Consumers should keep and use their current EpiPens if needed until they get a replacement. Consumers should contact Stericycle at 1-877-650-3494.

You should contact your physician or healthcare provider if you have experienced any problems that may be related to taking or using this medication.



GlucaGen HypoKit – Novo Nordisk, Inc.

On September 8, 2016, the U.S. Food and Drug Administration (FDA) announced that the drug manufacturer, Novo Nordisk, Inc. initiated a voluntary recall of six batches of the GlucaGen HypoKit. This recall includes the following batch numbers:

  • Batch: FS6X270, Expiry: 09/30/2017
  • Batch: FS6X296, Expiry: 09/30/2017
  • Batch: FS6X538, Expiry: 09/30/2017
  • Batch: FS6X597, Expiry: 09/30/2017
  • Batch: FS6X797, Expiry: 09/30/2017
  • Batch: FS6X875, Expiry: 09/30/2017

This recall has been initiated due to two customer complaints involving detached needles on the syringe with Sterile Water for Injection. GlucaGen HypoKit is indicated for the treatment of severe hypoglycemia (low blood sugar) in patients with diabetes who are treated with insulin. A syringe with a detached needle cannot be used as prescribed.

Untreated hypoglycemia can eventually lead to unconsciousness and seizures, which can prove fatal. If the blood glucose levels are not quickly restored, continuing hypoglycemia can lead to a decline in brain glucose levels which manifests through a variety of symptoms including cognitive dysfunction, sweating, tremors, convulsion and eventually coma or death.

You should contact your physician or healthcare provider if you have experienced any problems that may be related to taking or using this medication.




Last updated: 4/24/2017